UK - Aquarius Origin invests in Conformetrix
Newly-launched Aquaris Origin Fund has acquired a minority stake in drug development company Conformetrix in a deal of undisclosed value.
Though no financial details have been disclosed, the fund typically invests a maximum of £750,000 at one time.
Manchester-based Conformetrix specialises in analysing natural molecules to help discover new drug treatments. The Manchester University spin-out was founded in 2008 and employs five people.
The Aquarius Origin Fund was launched less than six months ago with the aim of raising £7.5m to invest in high growth potential unlisted companies based predominately in the north of England. Its fund is made up of cash from high net worth individuals.
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Czech Republic-headquartered family office is targeting DACH and CEE region deals
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Ex-Rocket Internet leader Bettina Curtze joins Swiss VC firm as partner and CFO
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Estonia-registered VC could bolster LP base with fresh capital from funds-of-funds or pension funds








